在用risankizumab治疗COVID-19后出现严重的牛皮疹:在16周后皮肤完全清除
Luciano Ibba1,2, Luigi Gargiulo1,2, Giulia Pavia1,2
1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele.
Dermatology reports
|April 16, 2024
概括
冠状病毒 (COVID-19) 流行病与牛皮病爆发有关. 在SARS-CoV-2感染后,一名患有严重斑块性牛皮的患者在接受瑞桑基祖马布治疗后实现了完整的皮肤清除.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- COVID-19流行病与免疫媒介性皮肤病的出现或恶化有关,包括牛皮.
- 牛皮是一种慢性炎症性皮肤疾病,影响生活质量.
研究的目的:
- 报告在SARS-CoV-2感染后出现严重斑块性牛皮炎的病例.
- 为了评估risankizumab在治疗COVID-19后牛皮的疗效和安全性.
主要方法:
- 一名38岁的女性患者在SARS-CoV-2感染四周后出现了严重的牛皮发作.
- 最初的阿西特雷丁治疗导致了不良事件.
- 治疗被切换为瑞桑基祖马布.
主要成果:
- 该患者的牛皮区域严重性指数 (PASI) 为25和皮肤病生活质量指数 (DLQI) 为18.
- 瑞桑基祖马布治疗导致皮肤在16周内完全清除.
- 在瑞桑基祖马布治疗期间没有报告任何不良事件.
结论:
- 瑞桑基祖马布是COVID-19引发的严重斑块性牛皮症爆发的有效和安全的治疗选择.
- 这一案例凸显了SARS-CoV-2感染对先前存在或新发展的皮肤病的潜在影响.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
136
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
136


